The Biotech Binary
An FDA approval decision is the purest binary event in financial markets. The drug is approved or it is not. The stock gaps up 40% or crashes 50%. There is no middle ground, no partial outcome, no "it depends." This binary nature makes FDA decisions ideal for prediction market contracts — and in 2026, both Kalshi and Polymarket offer contracts on major drug approval decisions that let you trade the probability directly rather than buying biotech stock and absorbing all the other noise that affects the share price.
The advantage of trading FDA approvals on prediction markets rather than through biotech stock: isolation. A biotech stock is affected by the approval decision, but also by market-wide risk sentiment, sector rotation, management changes, manufacturing issues, competitor developments, and a hundred other factors. A prediction market contract on "Will the FDA approve Drug X by Date Y" isolates the single variable you have a view on. If your edge is in understanding FDA regulatory dynamics, prediction markets let you monetize that edge without diluting it with stock-market noise.
How FDA Contracts Work
Kalshi lists FDA approval contracts when a drug has a scheduled PDUFA date (Prescription Drug User Fee Act deadline — the date by which the FDA must make a decision). The contract settles at $1.00 if the FDA issues an approval letter or $0.00 if it issues a Complete Response Letter (CRL, essentially a rejection or request for more data). The settlement source is the FDA's official announcement.
Contract prices typically range from $0.30 to $0.85 depending on the drug's clinical data, advisory committee recommendation, and the FDA's historical approval rate for similar drugs. A contract at $0.65 implies the market gives the drug a 65% chance of approval. If you believe the true probability is higher based on your analysis of the clinical trial data, you buy. If you believe it is lower, you sell.
Where the Edge Lives in FDA Trading
Advisory committee votes are the strongest pre-decision signal. The FDA convenes an advisory committee (AdCom) of external experts to review the drug's data and vote on whether it should be approved. AdCom votes are public and occur weeks before the PDUFA date. The FDA follows the AdCom recommendation approximately 75% of the time for positive votes and approximately 90% of the time for negative votes. After a positive AdCom vote, prediction market contracts often underprice the approval probability because traders anchor on the 25% overrule rate without adjusting for the specific drug's data quality.
Clinical trial data interpretation separates informed traders from the crowd. Most prediction market participants read the headline results (primary endpoint met or missed) without understanding the nuances. Was the p-value barely significant (p=0.048) or highly significant (p=0.001)? Were the secondary endpoints consistent? What was the safety profile? How did subgroup analyses look? The FDA reviews the full dataset, not the headline. Traders who can read and interpret clinical study reports have an enormous edge over those who rely on press releases.
FDA precedent analysis provides base rates that improve probability estimates. The FDA's behavior is more predictable than most traders realize. For a given therapeutic area, you can calculate the historical approval rate for drugs with similar clinical profiles. Oncology drugs with statistically significant overall survival improvements have been approved at a 90%+ rate. CNS drugs with modest efficacy and complex side effect profiles have been approved at roughly 50%. These base rates anchor your probability estimate before you layer on drug-specific analysis.
Timing Your FDA Trades
FDA approval contracts exhibit a predictable price pattern driven by the event timeline.
Months before PDUFA: Prices are volatile and driven by clinical data releases, conference presentations, and competitor developments. This is when the most mispricing occurs because the participant base is small and liquidity is thin. If you have a strong thesis based on clinical data, this is the best time to build your position — cheap entry with maximum time for the thesis to play out.
Weeks before AdCom (if applicable): Prices stabilize as the market forms a consensus view. AdCom briefing documents are released 1-2 days before the meeting — these FDA staff reviews contain the agency's preliminary analysis and often reveal the likely recommendation. Prices move sharply when briefing documents are released, creating a compressed trading window for fast analysis.
After AdCom, before PDUFA: Prices typically converge toward the AdCom-implied probability. A positive AdCom vote pushes contracts to $0.70-0.85. A negative vote pushes them to $0.15-0.35. The spread around the AdCom-implied level represents uncertainty about whether the FDA will follow the recommendation. Trading in this window requires a view on the FDA's likelihood of deviation.
Day of PDUFA: Prices move to extremes ($0.90+ or $0.10-) as the announcement approaches. The FDA typically issues decisions after market close. Some traders exit positions before the announcement to lock in gains; others hold for the full binary outcome. The optimal approach depends on your risk tolerance and the price you entered at.
Risk Management for FDA Trades
FDA outcomes are genuinely binary, which means position sizing is critical. Never allocate more than 5% of your prediction market balance to a single FDA contract. A drug with an 80% implied probability of approval still has a 20% chance of rejection — and if you have oversized your position, a single CRL can devastate your account.
Diversify across multiple PDUFA dates and therapeutic areas. The FDA's decisions on different drugs are largely independent events (one approval does not significantly change the probability of another). A portfolio of 10-15 FDA contracts, each sized at 3-5% of your balance, provides diversification that smooths returns and reduces the impact of any single binary outcome.
Consider the asymmetry of your edge. If you believe a drug will be approved and the market prices it at $0.60, your maximum upside is $0.40 per contract. If you are wrong, your maximum loss is $0.60 per contract. The risk-reward ratio is 0.67:1 — you need to be right more than 60% of the time to be profitable at this price. Adjust your position size based on not just your conviction level but also the mathematical payoff structure. Higher-priced contracts require higher accuracy rates to be profitable.
The Biotech Prediction Market Edge
FDA approval prediction markets are one of the purest applications of specialized knowledge in event trading. The barrier to entry is understanding clinical data, regulatory precedent, and FDA decision-making patterns — knowledge that is freely available in scientific publications, FDA guidance documents, and historical databases. The traders who invest the time to develop this domain expertise earn returns that reflect the intellectual barrier, not capital requirements. You do not need a large account. You need a large understanding of how the FDA thinks. Build the knowledge and the returns follow.
